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CLINICAL GUIDELINES
ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von
Willebrand disease
Paula D. James,1 Nathan T. Connell,2 Barbara Ameer,3,4 Jorge Di Paola,5 Jeroen Eikenboom,6 Nicolas Giraud,7 Sandra Haberichter,8
Vicki Jacobs-Pratt,9 Barbara Konkle,10,11 Claire McLintock,12 Simon McRae,13 Robert R. Montgomery,14 James S. O’Donnell,15
Nikole Scappe,16 Robert Sidonio Jr,17 Veronica H. Flood,14,18 Nedaa Husainat,19 Mohamad A. Kalot,19 and Reem A. Mustafa19
1Department of Medicine, Queen’s University, Kingston, ON, Canada; 2Brigham and Women’s Hospital, Harvard Medical School, Boston, MA; 3Pharmacology Consulting,
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Background: vonWillebrand disease (VWD) is the most common inherited bleeding disorder known in
humans. Accurate and timely diagnosis presents numerous challenges.
Objective: These evidence-based guidelines of the American Society of Hematology (ASH),
the International Society on Thrombosis and Haemostasis (ISTH), the National Hemophilia
Foundation (NHF), and the World Federation of Hemophilia (WFH) are intended to support patients,
clinicians, and other health care professionals in their decisions about VWD diagnosis.
Methods: ASH, ISTH, NHF, and WFH established a multidisciplinary guideline panel that
included 4 patient representatives and was balanced to minimize potential bias from conflicts of
interest. The Outcomes and Implementation Research Unit at the University of Kansas Medical
Center (KUMC) supported the guideline-development process, including performing or updating
systematic evidence reviews up to 8 January 2020. The panel prioritized clinical questions and
outcomes according to their importance for clinicians and patients. The panel used the Grading
of Recommendations Assessment, Development and Evaluation (GRADE) approach, including
GRADE Evidence-to-Decision frameworks, to assess evidence and make recommendations, which
were subsequently subject to public comment.
Results: The panel agreed on 11 recommendations.
Conclusions: Key recommendations of these guidelines include the role of bleeding-assessment tools
in the assessment of patients suspected of VWD, diagnostic assays and laboratory cutoffs for type 1
and type 2 VWD, how to approach a type 1 VWD patient with normalized levels over time, and the role of
genetic testing vs phenotypic assays for types 2B and 2N. Future critical research priorities are also
identified.
Summary of recommendations
These guidelines are based on updated and original systematic reviews of evidence conducted
under the direction of the Outcomes and Implementation Research Unit at the University
of Kansas Medical Center (KUMC). The panel followed best practices for guideline develop-
ment recommended by the Institute of Medicine and the Guidelines International Network
(G-I-N).1-3 The panel used the Grading of Recommendations Assessment, Development
and Evaluation (GRADE) approach4-10 to assess the certainty in the evidence and formulate
recommendations.
Submitted 3 September 2020; accepted 23 October 2020; published online 12
January 2021. DOI 10.1182/bloodadvances.2020003265.
Data for the Evidence-to-Decision frameworks will be publicly available via Web links
from the online version of the document.
The full-text version of this article contains a data supplement.
© 2021 by The American Society of Hematology
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von Willebrand disease (VWD) is a common, inherited bleeding
disorder. The current classification includes types 1 and 3, which
are characterized by quantitative deficiencies of von Willebrand
factor (VWF), as well as types 2A, 2B, 2M, and 2N, which are
qualitative variants. Clinically, VWD patients experience exces-
sive mucocutaneous bleeding, including heavy menstrual bleed-
ing, epistaxis, easy bruising, prolonged bleeding from minor
wounds and the oral cavity, and gastrointestinal bleeding, as well
as bleeding after dental work, childbirth, and surgery, with
musculoskeletal bleeding also seen in the most severe cases.
Treatment includes adjunctive therapies, such as tranexamic
acid, and therapies that directly increase the levels of VWF, such
as desmopressin and VWF concentrates. The accurate and
timely diagnosis of VWD remains a challenge for clinicians and
patients.
Please see Figure 1 for an overall algorithm addressing the
diagnosis of VWD.
Interpretation of strong and
conditional recommendations
The strength of a recommendation is expressed as either strong
(“the guideline panel recommends...”), or conditional (“the guideline
panel suggests…”) and has the following interpretation:
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Figure 1. An overall algorithm addressing the diagnosis of VWD. The numbers in the yellow circles correspond to guideline questions. VWF levels refer to VWF antigen
(VWF:Ag) and/or platelet-dependent VWF activity. The algorithm says VWF level 30 to 50 for simplicity; this refers to VWF levels of 0.30 to 0.50 IU/mL, with the caveat that
the lower limit of the normal range as determined by the local laboratory should be used if it is ,0.50 IU/mL. *Men and children, referred to a hematologist and/or first-degree
relative affected with VWD. BS, bleeding score; CBC, complete blood count; DDAVP, desmopressin; FVIII, factor FVIII; FVIII:C, FVIII coagulant activity; PT, prothrombin time;
PTT, partial thromboplastin time; r/o, rule out; TT, thrombin time; VWF:CB/Ag, ratio of VWF collagen binding to antigen; VWF:FVIIIB, VWF FVIII binding.
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Strong recommendation
c For patients: Most individuals in this situation would want the
recommended course of action, and only a small proportion
would not.
c For clinicians: Most individuals should follow the recommended
course of action. Formal decision aids are not likely to be needed
to help individual patients make decisions consistent with their
values and preferences.
c For policy makers: The recommendation can be adopted as
policy in most situations. Adherence to this recommendation
according to the guideline could be used as a quality criterion or
performance indicator.
c For researchers: The recommendation is supported by cred-
ible research or other convincing judgments that make
additional research unlikely to alter the recommendation.
On occasion, a strong recommendation is based on low or
very low certainty in the evidence. In such instances, further
research may provide important information that alters the
recommendations.
Conditional recommendation
c For patients: The majority of individuals in this situation would
want the suggested course of action, but many would not.
Decision aids may be useful in helping patients to make decisions
consistent with their individual risks, values, and preferences.
c For clinicians: Recognize that different choices will be appropri-
ate for individual patients and that you must help each patient
arrive at a management decision consistent with their values and
preferences. Decision aids may be useful in helping individuals to
make decisions consistent with their individual risks, values, and
preferences.
c For policy makers: Policy making will require substantial
debate and involvement of various stakeholders. Performance
measures about the suggested course of action should focus
on whether an appropriate decision-making process is duly
documented.
c For researchers: This recommendation is likely to be strength-
ened (for future updates or adaptation) by additional research.
An evaluation of the conditions and criteria (and the related
judgments, research evidence, and additional considerations)
that determined the conditional (rather than strong) recommen-
dation will help identify possible research gaps.
Interpretation of good practice statements
As described by the GRADE Guidance Group, good practice
statements endorse interventions or practices that the guide-
line panel agreed have unequivocal net benefit yet may not be
widely recognized or used.11 Good practice statements in
these guidelines are not based on a systematic review of
available evidence. Nevertheless, they may be interpreted as
strong recommendations.
Recommendations
Bleeding-assessment tools. RECOMMENDATION 1. For patients with a
low probability of VWD (eg, seen in the primary care setting), the
panel recommends using a validated bleeding-assessment tool
(BAT) as an initial screening test to determine who needs spe-
cific blood testing over nonstandardized clinical assessment
(strong recommendation based on moderate certainty in the
evidence from diagnostic accuracy studies ÅÅÅ◯).
Remarks:
c This recommendation applies predominantly to adult women, as
the data supporting the use of a BAT as a screening tool is
strongest in this patient group.
c The quality of nonstandardized clinical assessment will vary
among the users of these guidelines.
c Specific blood testing for VWD refers to VWF antigen (VWF:
Ag), platelet-dependent VWF activity (eg, VWF glycoprotein IbM
[VWF:GPIbM]), and factor VIII (FVIII) coagulant activity (FVIII:C).
RECOMMENDATION 2. For patients with an intermediate proba-
bility of VWD (eg, referred to a hematologist), the panel
suggests against relying on a BAT to decide whether to order
specific blood testing (conditional recommendation based on
moderate certainty in the evidence from diagnostic accuracy
studies ÅÅÅ◯).
Remarks:
c This recommendation addresses patients with an intermedi-
ate VWD pretest probability (;20%) corresponding to those
typically referred for hematology evaluation because of an abnormal
personal bleeding history or abnormal initial laboratory tests
(eg, prolonged activated partial thromboplastin time [aPTT])
(including men and children).
c Beyond their utility as a screening test in the primary care
setting, BATs can be used in the referral setting to assess
and document the severity of bleeding and can be used in
conjunction with specific blood testing as part of the initial
diagnostic approach.
c Specific blood testing for VWD refers to VWF:Ag, platelet-
dependent VWF activity (eg, VWF:GPIbM), and FVIII:C.
RECOMMENDATION 3. For patients with a high probability of
VWD (eg, affected first-degree relative), the panel recom-
mends against relying on a BAT to decide whether to order
specific blood testing (strong recommendation based on
moderate certainty in the evidence from diagnostic accuracy
studies ÅÅÅ◯).
Remarks:
c This recommendation addresses patients with a high VWD
pretest probability (;50%) corresponding to those typically
referred for hematology evaluation because of an affected first-
degree relative regardless of their bleeding symptoms or initial
laboratory tests (including men and children).
c Beyond their utility as a screening test in the primary care
setting, BATs can be used in the referral setting to assess
and document the severity of bleeding and can be used in
conjunction with specific blood testing as part of the initial
diagnostic approach.
c Specific blood tests for VWD refer to VWF:Ag, platelet-
dependent VWF activity (eg, VWF:GPIbM), and FVIII:C.
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Assays of platelet-binding activity of VWF. RECOMMENDATION 4.
The panel suggests newer assays that measure the platelet-binding
activity of VWF (eg, VWF:GPIbM, VWF:GPIbR) over the VWF
ristocetin cofactor assay (VWF:RCo) (automated or nonauto-
mated assay) for the diagnosis of VWD (conditional recommen-
dation based on low certainty in the evidence from diagnostic
accuracy studies ÅÅ◯◯).
GOOD PRACTICE STATEMENT. VWF activity assays should be
performed in a laboratory with appropriate expertise.
VWF levels that normalize with age. RECOMMENDATION 5.
The panel suggests reconsidering the diagnosis as opposed to
removing the diagnosis for patients with previously confirmed type 1
VWD who now have VWF levels that have normalized with age
(conditional recommendation based on very low certainty in the
evidence of effects Å◯◯◯).
Remarks:
c With this recommendation, the panel worked under the
assumption that the original diagnosis of type 1 VWD was
accurate.
c Aging and comorbidities are known to increase VWF levels.
However, the association between the increased VWF levels
and bleeding symptoms is not established.
c Decisions about reconsidering or removing the diagnosis should
consider the patient’s values and preferences and be informed
by a shared decision-making process.
Type 1 VWD. RECOMMENDATION 6. The panel recommends a VWF
level of ,0.30 IU/mL regardless of bleeding, and for patients with
abnormal bleeding, a VWF level of ,0.50 IU/mL to confirm the
diagnosis of type 1 VWD (strong recommendation based on low
certainty in the evidence of effects ÅÅ◯◯).
Remarks:
c VWF level(s) refers to VWF:Ag and/or platelet-dependent VWF
activity (eg, VWF:GPIbM).
c The lower limit of the normal range as determined by the local
laboratory should be used if it is ,0.50 IU/mL. ABO-specific
reference ranges are not required.
c VWF is an acute-phase reactant that increases in response to a
variety of stimuli (eg, bleed, trauma, pregnancy). VWD di-
agnostic testing should be performed when patients are at a
baseline state of health.
Type 1C VWD. RECOMMENDATION 7. The panel suggests
against using VWF propeptide (VWFpp)/VWF:Ag (the ratio
of VWF propeptide to antigen) and rather using a desmo-
pressin trial with 1- and 4-hour postinfusion blood work to
confirm increased VWF clearance for patients with VWD
suspected of type 1C (conditional recommendation based
on low certainty in the evidence from diagnostic accuracy
studies ÅÅ◯◯).
Type 2 VWD. RECOMMENDATION 8. The panel suggests against
a platelet-dependent VWF activity/VWF:Ag ratio ,0.5 cutoff,
and rather using a higher cutoff of ,0.7 to confirm type 2
VWD (2A, 2B, or 2M) for patients with an abnormal initial
VWD screen (conditional recommendation based on very low
certainty in the evidence from diagnostic studies Å◯◯◯).
Remark:
c Some patients with type 2 VWD have normal VWF:Ag and
platelet-dependent VWF activity but a low ratio of platelet-
dependent VWF activity/VWF:Ag.
RECOMMENDATION 9. The panel suggests either VWF multimer
analysis or VWF collagen binding (VWF:CB)/VWF:Ag (the
ratio of VWF collagen binding to antigen) to diagnose type 2
VWD for patients suspected of type 2A, 2B, or 2M in need of
additional testing (conditional recommendation based on very
low certainty in the evidence from diagnostic accuracy studies
Å◯◯◯).
Remark:
c Most laboratories that do the VWF:CB assay use type I and/or III
collagen, which is known to be a surrogate for the presence of
high-molecular-weight VWF.
RECOMMENDATION 10. The panel suggests targeted genetic testing
over low-dose ristocetin-induced platelet agglutination (RIPA) to
diagnose type 2B VWD for patients suspected of type 2A or 2B in
need of additional testing (Figure 2) (conditional recommendation
based on low certainty in the evidence from diagnostic accuracy
studies ÅÅ◯◯).
RECOMMENDATION 11. The panel suggests using either VWF FVIII
binding (VWF:FVIIIB) or targeted genetic testing (when available)
for patients with suspected type 2N VWD in need of additional
testing (Figure 3) (conditional recommendation based on low
certainty in the evidence from diagnostic accuracy studies
ÅÅ◯◯).




















Figure 2. An algorithm for the diagnosis of type 2B VWD. GPIb, glycoprotein Ib;
RIPA, ristocetin-induced platelet agglutination.
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Values and preferences These recommendations place the
highest value on not missing the diagnosis in affected patients
in order to ensure access to care. The panel considered the
following outcomes as critical for clinical decision-making
across questions: major bleeding, transfusion and treat-
ment, gastrointestinal bleeding, blood loss, symptom sever-
ity, minor bleeding, mortality, and unnecessary testing. These
outcomes will be affected by the accurate diagnosis of different
subtypes of VWD and avoiding inaccurate mislabeling of
patients.
Explanations and other considerations These recommen-
dations take into consideration cost and cost-effectiveness,
resource requirements, impact on health equity, acceptability,
and feasibility. Many included studies suffered from a high
risk of bias due to the lack of clear reference standards and
issues with patient selection.
Introduction
Aims of these guidelines and specific objectives
The purpose of these guidelines is to provide evidence-based
recommendations on the diagnosis of VWD. The primary
goals of these guidelines are to review, critically appraise, and
implement evidence-based recommendations that will im-
prove the accurate identification of affected patients while
minimizing inappropriate testing and the harms of overdiag-
nosis. Through improved provider and patient education using
the available evidence and evidence-based recommenda-
tions, these guidelines aim to provide clinical decision sup-
port for shared decision-making that will result in accurate
VWD diagnoses, which will lead to improved education and
counseling of patients as well as effective treatment and
prevention of bleeding episodes. The target audience includes
hematologists, general practitioners, internists, other clinicians and
decision-makers, and patients. Policy makers who may be inter-
ested in these guidelines include those involved in developing
local, national, or international plans with the goal of improving
the lives of patients living with VWD. This document may also
serve as the basis for adaptation by local, regional, or national
guideline panels.
Description of the health problem
In 1926, a Finnish physician, Erik von Willebrand, published a
description of a new bleeding disorder that he observed in a family
living in the Åland Islands in the Baltic Sea.12 The index case was a
young woman who bled to death at the time of her fourth menstrual
period; many other family members also suffered from excessive
bleeding. In the original report, the disease was referred to as
“pseudohemophilia”; however, it later came to be known as VWD.
VWD is caused by deficiency or dysfunction of the multimeric
glycoprotein VWF, which plays key hemostatic roles in the
circulation, including platelet adhesion and aggregation at sites of
vascular injury, and acts as a chaperone for FVIII.13 The VWF gene
is located on the long arm of chromosome 12 and comprises 52
exons that encode 2813 amino acids.14
VWD is characterized by excessive mucocutaneous bleeding, such
as heavy menstrual bleeding, epistaxis, easy bruising, prolonged
bleeding fromminor wounds and the oral cavity, and gastrointestinal
Patients suspected of type 2N VWD
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Figure 3. An algorithm for the diagnosis of type 2N VWD.
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bleeding, as well as bleeding after dental work, childbirth, and
surgery, with musculoskeletal bleeding, including joint bleeding
seen in more severe cases.13 It is the most common bleeding
disorder known in humans and is inherited equally between men
and women; however, women are more likely to come to medical
attention because of gynecologic and obstetric bleeding. VWD
prevalence estimates range from ;1 in 100 to 1 in 10 000.13,15-17
At the level of primary care,;1 in 1000 individuals are affected and
require medical attention for bleeding.18,19 The current Interna-
tional Society on Thrombosis and Haemostasis (ISTH) classifica-
tion recognizes 3 types: type 1 is a partial quantitative deficiency
of VWF, type 2 is caused by qualitative abnormalities of VWF, and
type 3 is a virtual absence of the VWF protein with associated very
low FVIII levels. Type 2 VWD is further divided into 4 subtypes:
type 2A is characterized by reduced or absent high-molecular-
weight VWF, type 2B results from a gain of function in VWF that
increases its affinity for platelets, type 2M is caused by reduced
VWF interactions with platelets or collagen, and type 2N results
from reduced binding of VWF to FVIII.20 The panel approached
this guideline within the framework of this classification system
with the addition of type 1C VWD, which is caused by increased
VWF clearance, given that it has management implications for
patients.21,22
A major challenge for affected patients is achieving an accurate and
timely diagnosis.23-26 Patients experience delays of 15 years or
more from the onset of bleeding symptoms to a VWD diagnosis,
and confusion remains about the distinction and importance of the
types and subtypes described above.27 Barriers to an accurate
diagnosis include a lack of understanding of the difference between
normal and abnormal bleeding symptoms, lack of clarity around an
appropriate diagnostic approach, and limited availability and
expertise of specialized laboratory testing. These considerations
informed the panel’s deliberations, with a high value being placed
on not missing affected patients. Overall, priorities for this guideline
were informed by an international survey of stakeholders, including
health care providers, patients, and caregivers, facilitated by the
partner organizations.28
Methods
The guideline panel developed and graded the recommendations
and assessed the certainty in the supporting evidence following the
GRADE approach.4-9,29,30 The overall guideline-development pro-
cess, including funding of the work, panel formation, management
of conflicts of interest, internal and external review, and organiza-
tional approval, was guided by American Society of Hematology
(ASH) policies and procedures derived from the G-I-N–McMaster
Guideline Development Checklist (http://cebgrade.mcmaster.ca/
guidecheck.html)31 and was intended to meet recommendations
for trustworthy guidelines by the Institute of Medicine (IOM)
and G-I-N.1-3
Organization, panel composition, planning,
and coordination
These guidelines were developed as a collaboration by ASH, the
International Society of Thrombosis and Haemostasis (ISTH), the
National Hemophilia Foundation (NHF), and the World Federation
of Hemophilia (WFH). The work of the panel was coordinated by
ASH and the Outcomes and Implementation Research Unit at
KUMC (funded by the collaborating organizations, under a paid
agreement). Project oversight was provided by the ASH Guideline
Oversight Subcommittee, which reported to the ASH Committee
on Quality. All 4 collaborating organizations made nominations,
with ASH vetting all individuals appointed to the guideline panel.
The Outcomes and Implementation Research Unit at KUMC
vetted and retained researchers to conduct systematic reviews
of evidence and coordinate the guideline-development process
including the use of the GRADE approach. The membership
of the panel and the systematic review team is described in
supplemental File 1.
The panel included pediatric and adult hematologists, internists,
and laboratory specialists who all had clinical and research
expertise on the guideline topic, as well as 4 patient representatives.
One chair was a content expert; the other chair was an expert in
guideline-development methodology. The panel also included a
clinical vice-chair who served on both the diagnosis and
management panels to ensure that their efforts were coordinated.
All panelists were full and equal voting members with regard to the
recommendations, with the exception of recusals as described in
the next section.
In addition to synthesizing evidence systematically, the methods
team from KUMC supported the guideline-development process,
including determining methods, preparing meeting materials, and
facilitating panel discussions. The panel’s work was done using
Web-based tools (www.surveymonkey.com and www.gradepro.org)
and face-to-face and online meetings.
Guideline funding and management of conflicts
of interest
Development of these guidelines was wholly funded by the 4
collaborating organizations: ASH, ISTH, NHF, and WFH. Organi-
zation staff supported panel appointments and attended meetings
but had no role in choosing the guideline questions or determining
the recommendations.
Members of the guideline panel received travel reimbursement
for attendance at in-person meetings. The patient representa-
tives received an honorarium of $200 dollars each. Through the
Outcomes and Implementation Research Unit at KUMC, some
researchers who contributed to the systematic evidence reviews
received salary or grant support. Other researchers participated to
fulfill requirements of an academic degree or program.
Conflicts of interest of all participants were managed according to
ASH policies based on IOM recommendations (2009) and G-I-N.3
Participants disclosed all financial and nonfinancial interests
relevant to the guideline topic. ASH staff and the ASH Guideline
Oversight Subcommittee reviewed the disclosures and com-
posed the guideline panel to include a diversity of expertise and
perspectives and avoid a majority of the panel having the same or
similar conflicts. The greatest attention was given to direct
financial conflicts with for-profit companies that could be directly
affected by the guidelines. A majority of the guideline panel,
including the cochairs, had no such conflicts. None of the
researchers from the Outcomes and Implementation Research
Unit at KUMC who contributed to the systematic evidence
reviews or who supported the guideline-development process
had any such conflicts.
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Recusal was used to manage certain conflicts.5,32-34 During
deliberations about recommendations, any panel member with a
current direct financial conflict in a commercial entity that marketed
any product that could be affected by a specific recommendation
participated in discussions about the evidence and clinical context
but was recused from making judgments or voting about individual
domains (eg, magnitude of desirable consequences) and the
direction and strength of the recommendation. The Evidence-to-
Decision (EtD) framework for each recommendation describes
which individuals were recused from making judgments about each
recommendation.
In July 2020, 1 panelist disclosed that during the guideline-
development process, he received a direct payment from a
company that could be affected by the guidelines. The activity
and disclosure occurred after the panel had agreed on recommen-
dations; therefore, the panelist was not recused. Members of the
Guideline Oversight Subcommittee reviewed the guidelines in
relation to this late disclosure and agreed that conflict was unlikely
to have influenced any of the recommendations.
Supplemental File 2 provides the complete disclosure-of-interest
forms of all panel members. Individuals disclosed direct financial
interests for 2 years prior to appointment in part A of the forms,
indirect financial interests in part B, and relevant other interests (not
mainly financial) in part C. Part D describes new interests disclosed
by individuals after appointment. Part E summarizes ASH decisions
about which interests were judged to be conflicts and how they
were managed, including through recusal.
Supplemental File 3 provides the complete disclosure-of-interest
forms of researchers who contributed to these guidelines.
Formulating specific clinical questions and
determining outcomes of interest
The panel used the GRADEpro guideline-development tool
(www.gradepro.org)35 and SurveyMonkey (www.surveymonkey.-
com) to brainstorm and then prioritize the questions described in
Table 1. To generate the initial list of possible questions, a working
group of clinicians, patients, and representatives from ASH, ISTH,
NHF, and WFH was established prior to the formation of the
guideline panel. A survey was developed by the KUMC methods
team to prioritize these questions, and it was then translated from
English into French and Spanish and widely publicized. Six hundred
one participants responded from 71 countries, including clinicians,
patients and caregivers, and members of allied health teams.
Detailed information about this process, which determined the 10
questions to be included in the guideline, was published in 2019.28
The panel selected outcomes of interest for each question a priori,
following the approach described in detail elsewhere.6 Although
acknowledging considerable variation in the impact on patient
outcomes, the panel considered the following outcomes as critical
for clinical decision-making across questions: major bleeding,
transfusion and treatment, gastrointestinal bleeding, blood loss,
symptom severity, minor bleeding, mortality, and unnecessary
testing. These outcomes will be affected by the accurate diagnosis
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Evidence review and development
of recommendations
For each guideline question, the methods team from the Outcomes
and Implementation Research Unit at KUMC prepared a GRADE
EtD framework, using the GRADEpro guideline-development
tool (www.gradepro.org).4,5,31 The EtD table summarized the
results of systematic reviews of the literature that were updated
or performed for this guideline. The EtD table addressed effects
of interventions, resource utilization (cost-effectiveness), values
and preferences (relative importance of outcomes), equity, accept-
ability, and feasibility. The guideline panel reviewed draft EtD
tables before, during, or after the guideline panel meeting, made
suggestions for corrections, and identified missing evidence. To
ensure that recent studies were not missed, searches (presented
in supplemental File 4) were updated on 8 January 2020, and panel
members were asked to suggest any studies that might have
been considered missed that fulfilled the inclusion criteria for the
individual questions.
Under the direction of the Outcomes and Implementation Research
Unit at KUMC, researchers followed the general methods outlined
in theCochrane Handbook for Systematic Reviews of Interventions
(handbook.cochrane.org) for conducting updated or new system-
atic reviews of intervention effects. For new reviews, risk of bias
was assessed at the health outcome level using the Cochrane
Collaboration’s risk-of-bias tool for nonrandomized studies
and the Quality Assessment of Diagnostic Accuracy Studies 2
(QUADAS-2) tool for test-accuracy studies.36 In addition to
conducting systematic reviews of test accuracy, the researchers
searched for evidence related to baseline risks, values, prefer-
ences, and costs, and summarized findings within the EtD
frameworks.4,5,30 Subsequently, the certainty in the body of
evidence (also known as quality of the evidence or confidence
in the estimated effects) was assessed for test-accuracy out-
comes following the GRADE approach based on the following
domains: risk of bias; precision, consistency, and magnitude of
the estimates of effects; directness of the evidence; and risk
of publication bias. The certainty was categorized into 4 levels:
very low (Å◯◯◯), low (ÅÅ◯◯), moderate (ÅÅÅ◯), and high
(ÅÅÅÅ).7,8,29,30,37-39
During a 2-day in-person meeting followed by online communication
and conference calls, the panel developed clinical recommenda-
tions based on the evidence summarized in the EtD tables. For each
recommendation, the panel took a population perspective and
came to consensus on the following: the certainty in the evidence,
the balance of benefits and harms of the compared management
options, and the assumptions about the values and preferences
associated with the decision. The guideline panel also explicitly took
into account the extent of resource use associated with alternative
management options. The panel agreed on the recommendations
(including direction and strength), remarks, and qualifications by
consensus based on the balance of all desirable and undesirable
consequences. The final guidelines, including recommendations,
were reviewed and approved by all members of the panel.
Interpretation of strong and
conditional recommendations
The recommendations are labeled as either “strong” or “conditional”
according to the GRADE approach. The words “the guideline panel
recommends” are used for strong recommendations, and “the
guideline panel suggests” for conditional recommendations. Table 2
provides GRADE’s interpretation of strong and conditional recom-
mendations by patients, clinicians, health care policy makers, and
researchers.
Document review
Draft recommendations were reviewed by all members of the
panel, revised, and then made available online on 6 April 2020
for external review by stakeholders including allied organiza-
tions, other medical professionals, patients, and the public;
51 individuals submitted comments. The document was revised
to address pertinent comments, but no changes were made to
recommendations. On 18 August 2020, the ASH Guideline
Oversight Subcommittee confirmed that the defined guideline-
development process had been followed; on 26 August 2020,
the ASH Committee on Quality confirmed that the defined
guideline-development process had been followed; and on
28 August 2020, the officers of the ASH Executive Commit-
tee approved submission of the guidelines for publication
under the imprimatur of ASH. On 25 August 2020, the WFH
confirmed that the defined guideline-development process
had been followed; on 27 August 2020, the NHF confirmed
that the defined guideline-development process had been
followed; and on 28 August 2020, the ISTH confirmed that the
defined guideline-development process had been followed.
The guidelines were then subjected to peer review by Blood
Advances.
How to use these guidelines
These guidelines are primarily intended to help clinicians make
decisions about diagnostic and treatment alternatives. Other
purposes are to inform policy, education, and advocacy, and to
state future research needs. They may also be used by patients.
These guidelines are not intended to serve or be construed as a
standard of care. Clinicians must make decisions on the basis of
the clinical presentation of each individual patient, ideally
through a shared process that considers the patient’s values
and preferences with respect to the anticipated outcomes of the
chosen option. Decisions may be constrained by the realities of a
specific clinical setting and local resources, including but not
limited to institutional policies, time limitations, and availability of
diagnostic tests and/or treatments. These guidelines may not
include all appropriate methods of care for the clinical scenarios
described. As science advances and new evidence becomes
available, recommendations may become outdated. Following
these guidelines cannot guarantee successful outcomes. ASH,
ISTH, NHF, and WFH do not warrant or guarantee any products
described in these guidelines.
Statements about the underlying values and preferences as well as
qualifying remarks accompanying each recommendation are its
integral parts and serve to facilitate more accurate interpretation.
They should never be omitted when quoting or translating
recommendations from these guidelines. Implementation of the
guidelines will be facilitated by the related interactive forthcoming
decision aids. The use of these guidelines is also facilitated by the
links to the EtD frameworks and interactive summary-of-findings
tables in each section.
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Recommendations
Bleeding-assessment tools
For patients suspected of VWD, should a BAT or nonstandar-
dized clinical assessment (not using a BAT) be used to screen
for VWD?
For patients (especially men and children) suspected of VWD with
a negative/normal bleeding score (based on a BAT), should blood
testing be done or is no blood testing needed?
Recommendation 1
For patients with a low probability of VWD (eg, seen in the
primary care setting), the panel recommends using a validated
BAT as an initial screening test to determine who needs spe-
cific blood testing over nonstandardized clinical assessment
(strong recommendation based on moderate certainty in the
evidence from diagnostic accuracy studies ÅÅÅ◯).
Remarks:
c This recommendation applies predominantly to adult
women, as the data supporting the use of a BAT as a
screening tool is strongest in this patient group.
c The quality of nonstandardized clinical assessment will
vary among the users of these guidelines.
c Specific blood testing for VWD refers to VWF:Ag,
platelet-dependent VWF activity (eg, VWF:GPIbM),
and FVIII:C.
Recommendation 2
For patients with an intermediate probability of VWD (eg,
referred to a hematologist), the panel suggests against
relying on a BAT to decide whether to order specific blood
testing (conditional recommendation based on moderate
certainty in the evidence from diagnostic accuracy studies
ÅÅÅ◯).
Remarks:
c This recommendation addresses patients with an inter-
mediate VWD pretest probability (;20%) correspond-
ing to those typically referred for hematology evaluation
because of an abnormal personal bleeding history or
abnormal initial laboratory tests (eg, prolonged aPTT)
(including men and children).
c Beyond their utility as a screening test in the primary
care setting, BATs can be used in the referral setting to
assess and document the severity of bleeding and can
be used in conjunction with specific blood testing as
part of the initial diagnostic approach.
c Specific blood testing for VWD refers to VWF:Ag, platelet-
dependent VWF activity (eg, VWF:GPIbM), and FVIII:C.
Recommendation 3
For patients with a high probability of VWD (eg, affected first-
degree relative), the panel recommends against relying on a
BAT to decide whether to order specific blood testing (strong
recommendation based on moderate certainty in the evidence
from diagnostic accuracy studies ÅÅÅ◯).
Remarks:
c This recommendation addresses patients with a high VWD
pretest probability (;50%) corresponding to those typically
referred for hematology evaluation because of an affected
first-degree relative regardless of their bleeding symptoms
or initial laboratory tests (including men and children).
c Beyond their utility as a screening test in the primary
care setting, BATs can be used in the referral setting to
assess and document the severity of bleeding and can
be used in conjunction with specific blood testing as
part of the initial diagnostic approach.
c Specific blood tests for VWD refer to VWF:Ag, platelet-
dependent VWF activity (eg, VWF:GPIbM), and FVIII:C.
Table 2. Interpretation of strong and conditional recommendations
Implications for Strong recommendation Conditional recommendation
Patients Most individuals in this situation would want the recommended
course of action, and only a small proportion would not.
The majority of individuals in this situation would want the
suggested course of action, but many would not. Decision aids
may be useful in helping patients to make decisions consistent
with their individual risks, values, and preferences.
Clinicians Most individuals should follow the recommended course of action.
Formal decision aids are not likely to be needed to help individual
patients make decisions consistent with their values and
preferences.
Recognize that different choices will be appropriate for individual
patients and that you must help each patient arrive at a
management decision consistent with their values and
preferences. Decision aids may be useful in helping individuals to
make decisions consistent with their individual risks, values, and
preferences.
Policy makers The recommendation can be adopted as policy in most situations.
Adherence to this recommendation according to the guideline
could be used as a quality criterion or performance indicator.
Policy making will require substantial debate and involvement of
various stakeholders. Performance measures about the
suggested course of action should focus on whether an
appropriate decision-making process is fully documented.
Researchers The recommendation is supported by credible research or other
convincing judgments that make additional research unlikely to
alter the recommendation. On occasion, a strong
recommendation is based on low or very low certainty in the
evidence. In such instances, further research may provide
important information that alters the recommendations.
The recommendation is likely to be strengthened (for future
updates or adaptation) by additional research. An evaluation of
the conditions and criteria (and the related judgments, research
evidence, and additional considerations) that determined the
conditional (rather than strong) recommendation will help
identify possible research gaps.
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Summary of the evidence. These recommendations were
stratified on 3 VWD prevalences to account for the frequency
of affected patients in different populations or clinical settings.
Recommendation 1 is intended for primary care practitioners assuming
a relatively low VWD prevalence in their clinic population, based on
literature that shows an ;3% prevalence of bleeding disorders in a
population with abnormal laboratory tests (eg, prolonged aPTT).40
Recommendation 2 assumes a 20% VWD prevalence and is based
on studies of consecutive patients referred to a hematology clinic,
typically because of a personal history of bleeding/bruising and/or
because of abnormal initial laboratory tests (eg, prolonged aPTT).41
Recommendation 3 assumes a 50% prevalence and is based on
individuals with an affected first-degree relative, in keeping with the
autosomal-dominant inheritance of most subtypes of the disease,
regardless of bleeding symptoms or the results of initial laboratory
tests.42,43 For these recommendations, 7 cohort studies that included
112 patients with a pooled sensitivity of 0.75 (95% confidence interval
[CI], 0.66-0.83) were assessed and judged to be highly accurate; the
sensitivity data were strongest for adult women. For specificity, the 7
cohort studies included 863 patients and had a pooled specificity of
0.54 (95% CI, 0.29-0.77) with moderate test accuracy.44-50 It is
important to note that the included studies assessed the use of
validated BATs vs not using a BAT rather than nonstandardized
testing. A detailed review of validated BATs can be found at
https://elearning.wfh.org/resource/compendium-of-assessment-tools/
#bleeding_assessment_tools1a42-60ce78a1-2573f205-9a34. The
EtD frameworks for these recommendations are available online at
https://guidelines.ash.gradepro.org/profile/RBzFDJwKapc and https://
guidelines.ash.gradepro.org/profile/aVdJ7pZVxu4.
Benefits, harms, and burden. The primary benefit of a BAT is
to identify patients who have VWD but would be missed without the
use of this tool. Additionally, BATs provide a standardized approach
to assessment. The panel considered not missing an affected
patient an important benefit, in addition to identifying patients in
a timely manner and decreasing unnecessary blood testing.
Furthermore, BATs provide educational value to patients and
clinical experts about bleeding symptoms and possible interven-
tions, and offer validation to patients by recognizing symptoms
of the disease. It is important to acknowledge that the identified
studies using BATs as a screening tool included mostly women:
they are most effective in this patient group.
The potential harms that could be caused by the use of a BAT
include the possibility of missing affected individuals who have
not manifested bleeding symptoms, such as men and children.
This key issue is why, in higher-prevalence settings, BATs should be
used in conjunction with specific blood testing rather than as the
sole screening tool to decide whether blood testing should be done.
BATs may also identify individuals who have bleeding disorders other
than VWD; however, appropriate laboratory testing should distinguish
those individuals. Additionally, some treatments will also be helpful for
individuals with other bleeding disorders (such as tranexamic acid or
combined oral contraceptives for heavy menstrual bleeding).
Other EtD criteria and considerations. Published BATs are
all freely available, but the administration of an expert-administered
version takes time in the clinic (including the requirement of appropriate
training and education for the individual administering the tool). The
self-administered BAT (Self-BAT) addresses this issue; however, it
is currently available only in English and French.46 The ISTH-BAT
(which is expert-administered) has been translated and is available
in German, Italian, Norwegian, Spanish,51 and Japanese (http://
square.umin.ac.jp/kintenka/index.html). BATs are generally accepted
by patients, as there is widespread familiarity with the completion of
health-related questionnaires across many clinical settings. BATs
(particularly expert-administered versions) may be less feasi-
ble in the primary care setting because of time and resource
constraints.
Conclusions and research needs for these recommendations.
The panel determined that there is a moderate certainty of evidence
for the test accuracy of the validated BATs. The panel agreed that
there is a net benefit from the use of BATs in a low-prevalence
setting but that in higher-prevalence settings, BATs should not be
used as a sole screening test to determine who needs additional
testing. Based on the available evidence, it is likely that the use of
BATs will identify patients with VWD in primary care settings to
help clinicians identify who needs additional, specialized labora-
tory testing. In other clinical settings, the use of BATs provides
a standardized method for the documentation and assessment
of the severity of bleeding symptoms as an adjunct to labora-
tory testing. With these recommendations, the panel considered
published data from the use of a number of different BATs;
however, many have evolved from the Vicenza bleeding question-
naire published in 2005 and have a high degree of overlap in their
questions and the scoring systems.52 Additionally, the ISTH recently
published a consensus BAT endorsed by that organization.53 The
panel identified the need for future studies focused on the sensi-
tivity and specificity of different score thresholds in the pediatric
population (particularly the adolescent population) and in men.
Assays of platelet-dependent activity of VWF
For patients suspected of VWD, should the VWF:RCo assay
(automated and nonautomated) or newer assays that reflect the
platelet-binding activity of VWF (eg, VWF:GPIbM, VWF:GPIbR) be
used to diagnose VWD?
Recommendation 4
The panel suggests newer assays that measure the platelet-
binding activity of VWF (eg, VWF:GPIbM, VWF:GPIbR) over the
VWF:RCo assay (automated or nonautomated) for the diagnosis
of VWD (conditional recommendation based on low certainty in
the evidence from diagnostic accuracy studies ÅÅ◯◯).
Good practice statement: VWF activity assays should be
performed in a laboratory with appropriate expertise.
Summary of the evidence. A total of 13 studies were identi-
fied as relevant for this question; however, 6 informed the final
recommendation. Data were reviewed for all published methods for
VWF:RCo, VWF:GPIbM, VWF:GPIbR, and VWF:Ab (supplemental
File 5); however, consistent with the recommendation of the ISTH
and other groups, we focused our deliberations on the first 3 as
direct measures of the platelet-binding activity of VWF.54,55 The
ranges of sensitivity and specificity across 4 studies for VWF:RCo
were 0.83 to 1.00 and 0.87 to 0.95, respectively.56-59 For VWF:
GPIbR, from 4 studies, it was 0.80 to 1.00 and 0.81 to 0.9756-59
and for VWF:GPIbM, from 2 studies, 0.62 to 0.82 and 0.90 to 0.97,
respectively.56-59 Therefore, the panel judged test accuracy to be
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generally comparable between the different assays. There was a
serious risk of bias in all studies because of the case-control design,
and only 2 studies reported on all 3 assays.56-59 Additionally, the
published studies indirectly addressed the question because the tests
were used to classify patients as opposed to making a new VWD
diagnosis. The EtD framework for this recommendation is available
online at https://guidelines.ash.gradepro.org/profile/VRjivq3oyEY.
Benefits, harms, and burden. The panel judged there to be
moderate benefits of the newer assays, reflecting the lower
coefficient of variation and higher reproducibility compared with
VWF:RCo. Additionally, although the published studies were
comparable in terms of test accuracy, they did not include a large
number of patients of African descent and therefore do not clearly
reflect the presence of VWF variants in that population that can affect
ristocetin binding with the VWF:RCo but do not affect VWF function
or represent the true risk of bleeding (eg, the D1472H sequence
variant).60,61 This creates the risk of overdiagnosis of these patients
with VWF:RCo, which was considered a potential harm.
Other EtD criteria and considerations. Although estimates vary
between countries, in general, the price is comparable between
assays but payer systems and levels of insurability vary widely. The
specialized technical nature of these assays (and the required expertise
to perform and interpret them) is another limitation to widespread
availability, as are issues of US Food and Drug Administration (FDA)
approval of the newer assays in the United States. Lastly, not all tests
are available in all laboratories, and decisions to switch from one assay
to another must take into account local circumstances.
Conclusions and research needs for this recommendation.
The guideline panel determined that there is low-certainty evidence
for a net health benefit from using newer assays that measure the
platelet-binding activity of VWF (eg, VWF:GPIbM, VWF:GPIbR)
over VWF:RCo for patients suspected of having VWD. Other EtD
criteria were generally in favor of using the newer assays. The panel
identified the need for additional research focused on the performance
of the assays in different racial/ethnic groups. Additionally, the panel
identified the need for international guidance on detailed characteris-
tics of appropriate laboratory expertise for VWF assays.
VWF levels that normalize with age
For patients with a historic diagnosis of type 1 VWDbut who now have
normal VWF levels, should the diagnosis of VWD be reconsidered,
or should it be removed?
Recommendation 5
The panel suggests reconsidering the diagnosis as opposed to
removing the diagnosis for patients with previously confirmed
type 1 VWD who now have VWF levels that have normalized
with age (conditional recommendation based on very low
certainty in the evidence of effects Å◯◯◯).
Remarks:
c With this recommendation, the panel worked under the
assumption that the original diagnosis of type 1 VWD
was accurate.
c Aging and comorbidities are known to increase VWF
levels. However, the association between the increased
VWF levels and bleeding symptoms is not established.
c Decisions about reconsidering or removing the diagno-
sis should consider the patient’s values and preferences
and be informed by a shared decision-making process.
Summary of the evidence. We identified 6 observational studies
that indirectly addressed this question and show that ;43% of VWD
patients have VWF levels that normalize with age62-67; however,
only 1 study adjusted for comorbidities that also could increase
VWF levels.62 Additionally, no studies longitudinally evaluated whether
the bleeding phenotype improved or resolved with increased VWF
levels. The widespread lack of age-specific normal ranges was also
identified as a complicating factor. The possibility that changes in the
ability of laboratories to measure VWF:RCo could be playing a role
was considered; however, in 1987, Gill et al published a cross-
sectional study of blood donors that showed a 0.01 IU/mL annual
increase in VWF levels between 20 and 60 years of age, suggesting
that the levels truly do increase with age.68 Whether that is in relation
to comorbidities or independent of them remains unclear. The EtD
framework for this recommendation is available online at https://
guidelines.ash.gradepro.org/profile/JHcpxNiXNGU.
Benefits, harms, and burden. Reconsidering (as opposed
to removing) the diagnosis would allow clinicians to consider and
test for a concomitant bleeding disorder (eg, a platelet function
disorder), particularly if this testing was not done at the time of the
type 1 VWD diagnosis. The panel acknowledges that the degree of
VWF normalization may influence management decisions for future
bleeds/procedures and that clinicians may choose to use tranexamic
acid alone and avoid desmopressin because of the concern of
cardiovascular complications and/or thrombosis in older patients.
The panel was concerned that a decision to remove a VWD diag-
nosis might result in a patient not receiving appropriate treatment of
a bleed or prior to a procedure, in addition to the patient not having
appropriate clinical follow-up and monitoring.
Other EtD criteria and considerations. No specific resources
would be required to remove a VWD diagnosis; however, the panel
acknowledges that the necessary discussion between physician
and patient is likely to be complicated and require adequate time.
Additionally, removal of a diagnosis could have significant effects
on insurance coverage in some countries. Reconsidering the
diagnosis also requires a detailed discussion and may not completely
avoid the issue of loss of insurance coverage; for example, in the United
States, patients with a diagnosis of bleeding of unknown cause (BUC)
are generally restricted from coverage of intranasal desmopressin. The
panel recognized that patients may have widely different views
on the acceptability of removing a VWD diagnosis. Patients with
minimal bleeding symptoms are likely to be less concerned than
those with significant bleeding, and a change in diagnosis may be
less acceptable to the latter group. Regardless, clear communi-
cation and shared decision-making in this critical aspect of patient
management is key, and one must keep in mind the physical and
psychosocial impact on the patient.
Conclusions and research needs for this recommendation.
The panel determined that there is very low certainty evidence for
a net health benefit by reconsidering as opposed to removing a
VWD diagnosis for patients with previously confirmed VWD who
now have VWF levels that have normalized with age. Multiple factors
make a firm diagnosis of VWD difficult. It must be acknowledged
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that mildly reduced VWF:Ag and VWF:RCo or VWF:GPIbM levels
do not always firmly establish a diagnosis of VWD; conversely,
levels at the lower end of the normal range do not always exclude
the diagnosis. Although the VWF:Ag assay has good precision
and reproducibility, VWF:RCo has greater variability, resulting in the
potential for misdiagnosis and/or misclassification. Data showing that
an increase in VWF levels with age is accompanied by a decrease in
bleeding risk/symptoms are not available, therefore, the removal of a
VWD diagnosis is very difficult. The panel identified a critical need for
longitudinal studies that correlate VWF levels with bleeding symptoms
as patients age, adjusted for comorbidities.
Type 1 VWD
For patients with an abnormal initial VWD screen (low VWF:Ag
and/or platelet-dependent VWF activity) suspected of type 1 VWD,
should the diagnostic cutoff be at VWF:Ag and/or VWF platelet-
dependent activity ,0.30 IU/mL or ,0.50 IU/mL?
Recommendation 6
The panel recommends a VWF level of ,0.30 IU/mL regard-
less of bleeding, and for patients with abnormal bleeding, a
VWF level of ,0.50 IU/mL to confirm the diagnosis of type 1
VWD (strong recommendation based on low certainty in the
evidence of effects ÅÅ◯◯).
Remarks:
c VWF level(s) refers to VWF:Ag and/or platelet-dependent
VWF activity (eg, VWF:GPIbM).
c The lower limit of the normal range as determined by
the local laboratory should be used if it is ,0.50 IU/mL.
ABO-specific reference ranges are not required.
c VWF is an acute-phase reactant that increases in response
to a variety of stimuli (eg, bleed, trauma, pregnancy). VWD
diagnostic testing should be performed when patients are
at a baseline state of health.
Summary of the evidence. A total of 9 observational
studies were reviewed that address this question, including studies
that evaluated the genetic basis of type 1 VWD,42,65,69,70
determined likelihood ratios (LRs) for type 1 VWD,42,71-73
correlated VWF levels with bleeding,65,71 and evaluated patients
referred for investigation of a possible bleeding disorder.18,74
The cutoff value of 0.30 IU/mL was evaluated based on expert
consensus and previous guideline recommendations.75 Patients
with VWF levels ,0.30 IU/mL were shown to have VWF
mutations detected 75% to 82% of the time.69,70 In contrast,
patients with VWF levels of 0.30 to 0.50 IU/mL had VWF
mutations detected 44% to 60% of the time.65,69,70 In terms of
LRs, patients with VWF levels of 0.30 to 0.40 IU/mL had an LR of
infinity, as VWF was confirmed in all cases with second-level
testing. For VWF levels of 0.41 to 0.50 IU/mL, the LR was 0.73
(0.41-1.30); for VWF levels of 0.51 to 0.60 IU/mL, the LR was
0.33 (0.18-0.62).71 Of critical importance, studies evaluating
the correlation of VWF levels and bleeding symptoms show a
similar bleeding phenotype across the range of VWF levels and
specifically do not show more severe bleeding in those with
VWF levels ,0.30 IU/mL.65,69 Additionally, 70 of 93 patients
with VWF levels of 0.30 to 0.50 IU/mL were investigated after a
bleeding episode: mucocutaneous bleeding was present in
35, 25 bled after surgery, and 10 bled after dental procedures. Ten
experienced .1 bleeding symptom.71 The EtD framework for this
recommendation is available online at https://guidelines.ash.gradepro.org/
profile/Ckc7oThe8q0.
Benefits, harms, and burdens. The issue of diagnostic cutoffs
is of great importance in certain health care systems, as it has a
major impact on who is able to access care. The panel judged that
those with VWF levels between 0.30 and 0.50 IU/mL and bleeding
symptoms would have a net health benefit from a clear type 1 VWD
diagnosis. The panel considered recommending that patients with
VWF levels between 0.30 and 0.50 IU/mL and a positive family
history should also be diagnosed with type 1 VWD (regardless of
bleeding symptoms); however, the risk of an inaccurate di-
agnosis in a family member was felt to be a significant concern.
Additionally, it was recognized that family structures vary widely
and might influence the possibility of a diagnosis, for example, if
someone had many female relatives who have heavy menstrual
bleeding. Furthermore, although the inheritance of type 1 VWD
in families with VWF levels ,0.30 IU/mL is autosomal dominant,
in families with VWF levels of 0.30 to 0.50 IU/mL, the issues
of incomplete penetrance and variable expressivity complicate
inheritance.70 In this latter group, the bleeding is likely to be complex,
with contribution from genes outside of VWF; a concomitant
bleeding disorder, such as a platelet function disorder, should
be considered. These issues led to debate about the cause of
bleeding in someone with milder reductions in VWF; however, these
patients are still likely to benefit from the many treatments that are
given for VWD, although they may suffer harms from side effects.
Other EtD criteria and considerations. Diagnosing individu-
als with type 1 VWD who have VWF levels between 0.30 and
0.50 IU/mL might result in more repeat testing for those on the
borderline. This could have accessibility and feasibility implications,
particularly for those who do not live in centers with specialized
coagulation laboratories.
Conclusions and research needs for this recommendation.
The panel determined that there is low-certainty evidence for
a net health benefit of less restrictive diagnostic criteria for
the diagnosis of type 1 VWD. Despite the low certainty in the
evidence, the panel decided on a strong recommendation for
2 reasons: (1) a high value was placed on an explicit diagnosis
to ensure access to care for those with a bleeding phenotype
and (2) to ensure international uniformity in diagnostic criteria
and the avoidance of center-specific thresholds based on
a conditional recommendation.76 Although a definite diagno-
sis of type 1 VWD is straightforward in those with VWF
levels ,0.30 IU/mL, the advantage of pursuing and assigning
a definitive diagnosis in mild or borderline cases was weighed
against the risk of overdiagnosis and overmedicalization.
As noted, the panel placed a high priority on not missing the
diagnosis, especially for patients with bleeding symptoms, in
order to ensure that management to treat/prevent bleeds is
provided. Research priorities were identified including de-
tailed data (including outcomes for bleeding with procedures
and prevalence of a concomitant bleeding disorder) for patients
with VWF levels between 0.30 and 0.60 IU/mL as well as the
correlation with bleeding symptoms and information about family
members of patients with type 1 VWD.
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Type 1C VWD
For patients suspected of type 1 VWDwith increased VWF clearance
(type 1C VWD), should the ratio of propeptide to VWF antigen
(VWFpp/VWF:Ag) or a desmopressin trial with 1- and 4-hour
postinfusion blood work be used to confirm increased VWF clearance?
Recommendation 7
The panel suggests against using the VWFpp/VWF:Ag (ratio of
VWF propeptide to antigen) and rather using a desmopressin trial
with 1- and 4-hour postinfusion blood work to confirm increased
VWF clearance for patients with VWD suspected of type 1C
should be used (conditional recommendation based on low cer-
tainty in the evidence from diagnostic accuracy studies ÅÅ◯◯).
Summary of the evidence. A decrease in VWF survival (or
increased VWF clearance) has long been suggested as a potential
mechanism for type 1 VWD and is now known to account for;15%
to 20% of cases.20,21 This was first clearly described for patients
with Vicenza-type VWD, known to be caused by the VWFmissense
mutation R1205H.77 It was subsequently shown that this pheno-
type could be identified by an increased VWFpp/VWF:Ag ratio,
given that the propeptide is stored in the Weibel-Palade bodies
of endothelial cells in a 1:1 ratio with the mature protein but
dissociates after secretion.78 If mature VWF is subject to enhanced
clearance, the ratio of VWFpp to VWF:Ag increases. The response
to desmopressin can also identify these patients, if a 4-hour
postinfusion time point is included and shows a .30% decrease
from the peak VWF level.79 Five studies were reviewed to address
this question, including 2 that evaluated the correlation between
the VWFpp/VWF:Ag ratio and VWF half-life78,79 and 3 that
reported on the correlation of the VWFpp/VWF:Ag ratio and VWF
mutation.21,22,80 No test-accuracy results were presented in the
included studies because of the lack of an accepted reference
standard to define type 1C VWD. In general, a higher VWFpp/
VWF:Ag ratio was associated with a shorter VWF half-life and a
higher rate of an identified VWFmutation, but it was noted that in some
patients, the ratio can be normal but the clearance of VWF rapid.79
The EtD framework for this recommendation is available online at
https://guidelines.ash.gradepro.org/profile/wBmLq8BFekg.
Benefits, harms, and burden. The accurate identification of
patients who have type 1C VWD has management implications,
as these patients may require VWF concentrate to treat/prevent
bleeds. A desmopressin trial, in addition to identifying patients with
increased VWF clearance, also provides very useful information to
the clinician about the utility of that treatment of an individual patient.
Not all patients can safely undergo a desmopressin trial, including
very young and very old patients, because of the risks associated
with desmopressin (eg, hyponatremia or thrombosis); in these
patients, the VWFpp/VWF:Ag ratio could be helpful.
Other EtD criteria and considerations. Desmopressin trials
require significant resources to complete in terms of nursing time,
clinic space, and laboratory costs. Repeated blood draws are
required, which could decrease acceptability for some patients. A
significant time commitment is also required to complete the trial,
including 1- and 4-hour postinfusion levels, resulting in patients
needing to make an extra visit to clinic and miss a day of work or
school; however, with a clear explanation of why the trial (and the
4-hour postinfusion level) is needed, it is likely that most patients
would agree to have it performed. Lastly, protocols for the
completion of desmopressin trials and definitions of responsive-
ness vary widely. Conversely, the VWFpp assay is simple to
perform and requires only a single blood draw, but it is not
available in most clinical laboratories.
Conclusions and research needs for this recommendation.
Overall, the panel determined that there is low certainty for a net
health benefit from the use of a desmopressin trial over the VWFpp/
VWF:Ag ratio for the identification of type 1C VWD. Feasibility and
acceptability concerns for desmopressin trials were judged to be
substantial, but this did not outweigh the lack of availability of the
VWFpp assay. Research priorities include the need for studies
addressing the sensitivity and specificity of various VWFpp/VWF:
Ag thresholds, the clearance and half-life of VWFpp, and whether
those variables are constant, in addition to studies that always
include the 4-hour postinfusion time point for desmopressin trials.
Type 2 VWD
For patients with an abnormal initial VWD screen (low VWF:Ag
and/or platelet-dependent VWF activity) suspected of type 2 VWD,
should a platelet-dependent VWF activity/VWF:Ag ratio cutoff of
,0.5 or a higher cutoff of ,0.7 be used to confirm type 2 VWD?
Recommendation 8
The panel suggests against a platelet-dependent VWF
activity/VWF:Ag ratio cutoff of ,0.5 and rather using a higher
cutoff of ,0.7 should be used to confirm type 2 VWD (2A,
2B, or 2M) for patients with an abnormal initial VWD screen
(conditional recommendation based on very low certainty in
the evidence from diagnostic accuracy studies Å◯◯◯).
Remark:
c Some patients with type 2 VWD have normal VWF:Ag
and platelet-dependent VWF activity but a low ratio of
platelet-dependent VWF activity/VWF:Ag.
Summary of the evidence. Six observational studies were
identified that addressed this question; all 6 evaluated diagnostic test
accuracy,59,81-85 and 1 also looked at VWFmutations felt to be causative
of type 2M VWD.83 The pooled sensitivity for the higher cutoff of,0.70
was 0.90 (95% CI, 0.83-0.94) compared with 0.58 to 0.79 for ,0.5.
Specificity was assumed to be 100% for ,0.5 but was not directly
available from the published studies. The panel judged there to be a
serious risk of bias in 4 studies due to the case-control study design
and serious unexplained heterogeneity between the studies. The EtD
framework for this recommendation is available online at https://
guidelines.ash.gradepro.org/profile/Orzbo0O_gbw.
Benefits, harms, and burden. The panel was less concerned
about false positives for this question, as additional testing, such
as VWF multimer analysis, the VWF:CB assay, and/or genotyp-
ing, is typically performed for type 2 VWD, providing further
clarification of the subtype. False negatives were judged to be of
greater importance by both clinical and patient experts because
of the concern of missing patients who would benefit from treatment.
The false-negative rate was much higher for the ,0.5 cutoff than
the ,0.7 cutoff (65 more false negatives of 1000 in a population
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with 30% prevalence). However, it should be noted that this question
applies to patients with abnormal initial VWD testing, making it more
likely that a patient would be misclassified as having type 1 VWD than
missed altogether.
Other EtD criteria and considerations. There would be no
direct change to cost of using different ratio cutoffs for type 2 VWD;
however, a higher cutoff is likely to result in more repeat testing and
additional assays being performed. Lack of widespread availability and
differing levels of insurance coverage of VWF assays were highlighted
as issues, in addition to variability in terms of clinical and laboratory
expertise about type 2 VWD. Problems with the VWF:RCo and false-
positive results in the African American population were also noted.
Conclusions and research needs for this recommendation.
The guideline panel determined that there is low-certainty evidence
for a net health benefit from using a VWF:RCo/VWF:Ag cutoff of
,0.7 over a lower cutoff of ,0.5 for patients suspected of type 2
VWD. Additional research is needed to understand variability in the
VWF:RCo in different ethnic groups.
For patients suspected of type 2A, 2B, or 2M VWD in need of
additional testing, should a VWF multimer analysis or a VWF:CB to
VWF:Ag ratio (VWF:CB/VWF:Ag) be used?
Recommendation 9
The panel suggests either VWF multimer analysis or
VWF:CB/VWF:Ag (ratio of VWF collagen binding to antigen)
to diagnose type 2 VWD for patients suspected of type 2A, 2B,
or 2M in need of additional testing (conditional recommenda-
tion based on very low certainty in the evidence from diagnostic
studies Å◯◯◯).
Remark:
c Most laboratories that do the VWF:CB assay use type I
and/or III collagen, which is known to be a surrogate for
the presence of high-molecular-weight VWF.
Summary of the evidence. There were a total of 10 studies
that addressed this question. Ten addressed diagnostic test
accuracy for types 2A and 2B59,85-93 and 6 for type 2M.87-90,92,93
For types 2A and 2B, the sensitivity of VWF:CB/VWF:Ag was
0.90 (95% CI, 0.78-0.96) and specificity was 0.95 (95% CI, 0.89-
0.98), vs a sensitivity of 0.90 (95% CI, 0.90-0.99) and specificity of
0.97 (95% CI, 0.94-0.99) for multimers. For type 2M VWD, the
sensitivity of VWF:CB/VWF:Ag was 0.98 (95%CI, 0.96-1.00) with
a specificity of 0.99 (95% CI, 0.98-1.00), vs a sensitivity of
0.86 (95%CI, 0.73-0.98) and a specificity of 0.97 (95%CI, 0.94-0.99)
for multimers. However, there was a serious risk of bias in many of
the studies because of the case-control design, and it must be
acknowledged that the centers doing the multimer analysis for these
studies were referral centers with significant experience and expertise.
Additionally, there was no consistent cutoff for the VWF:CB/VWF:Ag
ratio. Lastly, type 2M VWD is defined by a normal multimer profile,
making this assay the reference standard for that subtype. The
EtD framework for this recommendation is available online at
https://guidelines.ash.gradepro.org/profile/26d0oeZn088.
Benefits, harms, and burden. The accurate identification of
patients with types 2A, 2B, or 2M is important for prognosis and for
family counseling. Patients with type 2 VWD generally have more
significant bleeding than those with type 1 VWD, and the family
histories are clearly autosomal dominant, without the issues of
incomplete penetrance or variable expressivity that complicate
milder forms of type 1 VWD.45 Desmopressin is relatively
contraindicated in type 2B VWD, as it may cause thrombocy-
topenia due to increased platelet binding; however, patients
suspected of having this subtype would usually have additional
testing performed, such as genetic testing, that would clarify the
subtype.94 Patients with type 2A or 2M are less likely to respond
to desmopressin, but this would be identified at the time of a
desmopressin trial.95 Other treatment decisions are not likely to
vary significantly between subtypes.
Other EtD criteria and considerations. The VWF:CB assay
is not widely available, and there are differences in the type of
collagen used. Collagen types I and III interact with the A3 domain
of VWF and type IV collagen with the A1 domain; as noted, most
laboratories that perform this assay use type I and/or III collagen.
VWF multimer analysis is technically challenging and is generally
much more expensive than the VWF:CB assay. Insurance coverage
for both assays varies widely.
Conclusions and research needs for this recommendation.
The panel determined that there is low-certainty evidence to
recommend either performing VWF multimer analysis or using the
VWF:CB/VWF:Ag ratio to identify type 2A, 2B, or 2M VWD.
Additional research is needed to assess the diagnostic test accuracy of
multimers in VWD patients who have known abnormal VWF:CB.
For patients suspected of type 2A or 2B VWD, should low-dose RIPA
or targeted genetic testing be used to diagnose type 2B VWD?
Recommendation 10
The panel suggests targeted genetic testing over low-dose
RIPA to diagnose type 2B VWD for patients suspected of type
2A or 2B in need of additional testing (Figure 2) (conditional
recommendation based on low certainty in the evidence from
diagnostic accuracy studies ÅÅ◯◯).
Summary of the evidence. We identified 15 studies that
addressed this question, 14 that reported the identification of type
2B VWD mutations,84,94-106 and 9 that reported phenotype-
genotype correlations in 2B VWD.84,94,97,98,100-103,105 The pooled
sensitivities were 1.00 (95% CI, 1.00-1.00) for genetic testing and
0.99 (95% CI, 0.60-1.00) for RIPA; specificity was not available
from the included studies. There was serious risk of bias because of
the case-control study design and serious issues with the reference
standard and/or index test bias in many of the studies; type 2B
VWD is often defined by the VWFmutation and/or the identification
of platelet agglutination with a low ristocetin concentration on RIPA.
The EtD framework for this recommendation is available online at
https://guidelines.ash.gradepro.org/profile/hGn1YO1dxh4.
Benefits, harms, and burden. The accurate identification of
type 2B VWD is important because it has relevance for prognosis
and also treatment. Patients with this subtype typically have a
more severe bleeding phenotype compared with other type 2
and type 1 VWD patients, and the bleeding risk has been shown
to correlate with the degree of thrombocytopenia.94 Additionally,
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desmopressin is relatively contraindicated because it can worsen
the thrombocytopenia.
Other EtD criteria and considerations. Pathogenic VWF
variants that cause type 2B VWD are found in exon 28; therefore,
targeted genetic testing for well-characterized missense mutations
is possible. Genetic testing is not available at all centers, but it is
relatively straightforward to ship samples for this type of analysis.
Likewise, RIPA is not available at all centers; however, that test
requires a fresh sample; therefore, shipping is not possible, limiting
accessibility to the test. Additionally, the methodology to perform a
RIPA is not standardized, and different concentrations of ristocetin
have been proposed as indicating a positive test (eg, 0.5 mg/mL
and 0.25 mg/mL). In general, patients accept having either test
performed; however, there are some patient groups that have
concerns about genetic tests (eg, some First Nations people).
Genetic testing is typically more expensive than RIPA, and
insurance coverage is variable.
Conclusions and research needs. The panel determined
that there is low-certainty evidence for a net health benefit
from the use of targeted genetic testing (when available)
over RIPA to diagnose type 2B VWD. Additional research,
focused on the diagnostic test accuracy of RIPA, would be
beneficial.
For patients suspected of type 2N VWD in need of additional
testing, should VWF:FVIIIB or targeted genetic testing be used to
diagnose type 2N VWD?
Recommendation 11
The panel suggests using either VWF:FVIIIB or targeted ge-
netic testing (when available) for patients with suspected type
2N VWD in need of additional testing (Figure 3) (conditional
recommendation based on low certainty in the evidence from
diagnostic accuracy studies ÅÅ◯◯).
Summary of the evidence. We identified 17 studies that
addressed this question, 16 that reported on the identification of
a type 2N mutation57,103,105,107-119 and 13 that reported the
correlation between assays.57,102,103,105,107,109-111,114-117,119 The
sensitivities of both genetic testing and the VWF:FVIIIB assay were
reported as 1.00 (95% CI, 1.00-1.00); however, both were used as
the reference standard, resulting in serious bias. Specificity was not
available from the included studies. There was also serious patient-
selection bias due to the case-control study design in all studies.
The EtD framework for this recommendation is available online at
https://guidelines.ash.gradepro.org/profile/HDVamZn5f-0.
Benefits, harms, and burden. The accurate identification of
type 2N VWD is important for a number of reasons. In contrast to
all other type 2 and type 1 VWD, type 2N is autosomal recessive,
which is critical for appropriate genetic counseling within families.
Type 2N VWD can be mistaken for hemophilia A because of the
low FVIII level, with critical treatment implications: patients with
hemophilia A are treated with FVIII concentrate; however, type 2N
VWD patients require VWF replacement therapy to prevent/treat
serious bleeds. Pathogenic VWF variants that cause type 2N VWD
are generally found in exons 18 to 20; however, novel variants that
have not been previously described or characterized can be found.120
In those cases, evidence of the phenotype is required (decreased
binding of FVIII by VWF, which would be identified by the VWF:FVIIIB
assay). However, doing only the VWF:FVIIIB assay will not be as
informative as genetic testing for family counseling, as patients with
type 2N VWDcan be homozygous for a single 2N variant or compound
heterozygous for 2 2N variants (and in both cases a child would
be heterozygous for a 2N allele and unlikely to manifest bleeding);
sometimes only a single 2N variant is found, in which case it is assumed
that there is coinheritance of a null allele (therefore, a child could be
heterozygous for 2N with no bleeding or could have type 1 VWD).
Additionally, if an F8 variant is identified as opposed to a VWF variant,
then the diagnosis can be confirmed as hemophilia A with appropriate
treatment and genetic counseling for X-linked inheritance.120
Other EtD criteria and considerations. Genetic testing is not
available at all centers, but it is relatively straightforward to ship
samples to reference laboratories for this type of analysis. Likewise,
VWF:FVIIIB is not available at all centers, but shipping of plasma is
possible. In general, patients accept having either test performed;
however, there are some patient groups that have concerns
about genetic testing (eg, some First Nations people). Genetic
testing is more expensive than the VWF:FVIIIB assay, and insurance
coverage is variable.
Conclusions and research needs for this recommendation.
The panel determined that there is low-certainty evidence to
suggest using either VWF:FVIIIB or genetic testing for patients
with suspected type 2N VWD. Indeed, the panel agreed that the
tests can be complementary in the diagnostic workup of patients.
Identifying a reference standard for type 2N VWD was identified as
a research priority.
What are others saying and what is new in
these guidelines?
Multiple published guidelines recommend a cutoff of ,0.30 IU/mL
for a definite diagnosis of type 1 VWD, with the US National
Institutes of Health National Heart, Lung, and Blood Institute
(NHLBI) guidelines stating that “this recommendation does not
preclude the diagnosis of VWD in individuals with VWF:RCo of
30 to 50 IU/dL if there is supporting clinical evidence and/or family
evidence for VWD.”75 The recommendation of the United Kingdom
Haemophilia Centre Doctors Organization (UKHCDO) states: “Patients
with an appropriate bleeding history and VWF activity 0.30-0.50 IU/mL
should be regarded as having primary hemostatic bleeding with
reduced VWF as a risk factor rather than VWD. We suggest
referring to this as ‘Low VWF’.”55 This guideline panel prioritized
ensuring access to medical care and therefore recommends a
level of ,0.30 IU/mL regardless of bleeding and a VWF level of
0.30 to 0.50 IU/mL for patients with abnormal bleeding to confirm
the diagnosis of type 1 VWD. There was significant concern that
the term “Low VWF” creates an unintentional barrier to patients
receiving appropriate care because of a lack of a clear diagnosis,
particularly in countries without universal health care systems. A
patient’s bleeding symptoms were the primary consideration for
this recommendation.
Recently, the NHF Medical and Scientific Advisory Council (MASAC)
raised concern about the critical importance of preanalytical variables
in VWD testing, and the possibility of false-positive results from
samples processed or shipped improperly.121 This guideline panel
acknowledges the significance of this issue in avoiding a misdiagnosis
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of VWD, which has been reported in a cohort of women being
investigated for a bleeding disorder.122
These guidelines focused on the most common inherited forms
of VWD; however, we would like to highlight the recently published
guidance document on the diagnosis and management of platelet-
type VWD from the ISTH Platelet Physiology Subcommittee123 and
several recent reviews on acquired von Willebrand syndrome.124,125
Limitations of these guidelines
The limitations of these guidelines are inherent in the low or very low
certainty in the evidence identified for many of the questions.
Plans for updating these guidelines
After publication of these guidelines, the collaborating organizations
will maintain them through surveillance for new evidence,
ongoing review by experts, and regular revisions based on
literature searches.
Updating or adapting recommendations locally
Adaptation of these guidelines will be necessary in many circum-
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103. Borràs N, Battle J, Pérez-Rodriguez A, et al. Molecular and clinical profile of von Willebrand disease in Spain (PCM-EVW-ES): comprehensive genetic
analysis by next-generation sequencing of 480 patients. Haematologica. 2017;102(12):2005-2014.
104. Kaur H, Ozelo M, Scovil S, James PD, Othman M. Systematic analysis of bleeding phenotype in PT-VWD compared to type 2B VWD using an electronic
bleeding questionnaire. Clin Appl Thromb Hemost. 2014;20(8):765-771.
105. Veyradier A, Boisseau P, Fressinaud E, et al; French Reference Center for vonWillebrand disease. A laboratory phenotype/genotype correlation of 1167
French patients from 670 families with von Willebrand disease: a new epidemiologic picture. Medicine (Baltimore). 2016;95(11):e3038.
106. Shen M-C, ChenM, MaG-C, et al. De novo mutation and somatic mosaicism of genemutation in type 2A, 2B and 2MVWD. Thromb J. 2016;14(suppl 1):36.
107. Taylor SL, Bromidge E, Savidge GF, Alhaq A. Evaluation of an automated screening assay for vonWillebrand disease type 2N.Clin Lab Haematol. 2002;
24(6):369-375.
108. Bowen DJ, Standen GR, Mazurier C, et al. Type 2N von Willebrand disease: rapid genetic diagnosis of G2811A (R854Q), C2696T (R816W),
T2701A (H817Q) and G2823T (C858F)–detection of a novel candidate type 2N mutation: C2810T (R854W). Thromb Haemost. 1998;80(1):
32-36.
109. Caron C, Mazurier C, Goudemand J. Large experience with a factor VIII binding assay of plasma von Willebrand factor using commercial reagents. Br J
Haematol. 2002;117(3):716-718.
110. Casonato A, Pontara E, Sartorello F, et al. Identifying carriers of type 2N vonWillebrand disease: procedures and significance.Clin Appl ThrombHemost.
2007;13(2):194-200.
111. Casonato A, Pontara E, Zerbinati P, Zucchetto A, Girolami A. The evaluation of factor VIII binding activity of von Willebrand factor by means of an ELISA
method: significance and practical implications. Am J Clin Pathol. 1998;109(3):347-352.
112. Casonato A, Galletta E, Sarolo L, Daidone V.Type 2N von Willebrand disease: characterization and diagnostic difficulties. Haemophilia. 2018;24(1):
134-140.
113. Corrales I, Ramı́rez L, Altisent C, Parra R, Vidal F. Rapid molecular diagnosis of von Willebrand disease by direct sequencing. Detection of 12 novel
putative mutations in VWF gene. Thromb Haemost. 2009;101(3):570-576.
114. Hampshire DJ, Abuzenadah AM, Cartwright A, et al. Identification and characterisation of mutations associated with von Willebrand disease in a Turkish
patient cohort. Thromb Haemost. 2013;110(2):264-274.
115. Rodgers SE, Lerda NV, Favaloro EJ, et al. Identification of vonWillebrand disease type 2N (Normandy) in Australia: a cross-laboratory investigation using
different methods. Am J Clin Pathol. 2002;118(2):269-276.
116. Schneppenheim R, Budde U, Krey S, et al. Results of a screening for von Willebrand disease type 2N in patients with suspected haemophilia A or von
Willebrand disease type 1. Thromb Haemost. 1996;76(4):598-602.
117. Veyradier A, Caron C, Ternisien C, Wolf M, Trossaert M, Fressinaud E, Goudemand J. Validation of the first commercial ELISA for type 2N von
Willebrand’s disease diagnosis. Haemophilia. 2011;17(6):944-951.
118. WangQY, Song J, Gibbs RA, Boerwinkle E, Dong JF, Yu FL. Characterizing polymorphisms and allelic diversity of vonWillebrand factor gene in the 1000
Genomes. J Thromb Haemost. 2013;11(2):261-269.

















L user on 24 February 2021
119. Zhukov O, Popov J, Ramos R, et al. Measurement of von Willebrand factor-FVIII binding activity in patients with suspected von Willebrand disease type
2N: application of an ELISA-based assay in a reference laboratory. Haemophilia. 2009;15(3):788-796.
120. James PD, Goodeve AC. von Willebrand disease. Genet Med. 2011;13(5):365-376.
121. Medical and Scientific Advisory Council (MASAC) of the National Hemophilia Foundation (NHF). MASAC Resolution on Off-Site Hemostasis Testing.
MASAC Document #262, approved by MASAC 8 August 2020. https://www.hemophilia.org/sites/default/files/document/files/262_Off-
Site_Hemostasis_Testing.pdf. Accessed 12 May 2020.
122. Jaffray J, Staber JM, Malvar J, et al. Laboratory misdiagnosis of von Willebrand disease in post-menarchal females: a multi-center study [published
correction appears in Am J Hematol. 2020;95(11):1432-1440]. Am J Hematol. 2020;95(9):1022-1029.
123. Othman M, Gresele P. Guidance on the diagnosis and management of platelet-type von Willebrand disease: a communication from the Platelet
Physiology Subcommittee of the ISTH. J Thromb Haemost. 2020;18(8):1855-1858.
124. Franchini M, Mannucci PM. Acquired von Willebrand syndrome: focused for hematologists. Haematologica. 2020;105(8):2032-2037.
125. Biguzzi E, Siboni SM, Peyvandi F. How I treat gastrointestinal bleeding in congenital and acquired von Willebrand disease. Blood. 2020;136(10):
1125-1133.

















L user on 24 February 2021
